Open Label Placebo in the Treatment of Low Back Pain

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients will be randomized to receive open-label (honestly described placebo) immediately at baseline or be eligible to receive the open-label treatment three weeks after the baseline measurements. Therefore all patients will be eligible to receive open-label placebo treatment for their chronic low back pain during the course of the study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Egas Moniz

Criteria

Inclusion Criteria:

• Male or female

• 18 years or older

• Low back pain complaints for a min. of 3 months

Exclusion Criteria:

• use of strong opioid analgesic and/or anticonvulsant medication;

• specific causes of back pain namely cancer, fractures and infections;

• complicated back problems (e.g. prior back surgery);

• conditions making treatment difficult (e.g. paralysis, psychoses);

• conditions that might confound treatment effects or interpretation of results (e.g. severe fibromyalgia, rheumatoid arthritis);

• concurrent care from other providers;

• conditions that affect safety of patient (e.g. pregnancy);

• concurrent medical legal issues.